291 related articles for article (PubMed ID: 33306682)
1. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
Luong XG; Stevens SK; Jekle A; Lin TI; Gupta K; Misner D; Chanda S; Mukherjee S; Williams C; Stoycheva A; Blatt LM; Beigelman LN; Symons JA; Raboisson P; McGowan D; Vandyck K; Deval J
PLoS One; 2020; 15(12):e0240338. PubMed ID: 33306682
[TBL] [Abstract][Full Text] [Related]
2. TG68, a Novel Thyroid Hormone Receptor-β Agonist for the Treatment of NAFLD.
Caddeo A; Kowalik MA; Serra M; Runfola M; Bacci A; Rapposelli S; Columbano A; Perra A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884910
[TBL] [Abstract][Full Text] [Related]
3. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Hormone Analogues: An Update.
Zucchi R
Thyroid; 2020 Aug; 30(8):1099-1105. PubMed ID: 32098589
[TBL] [Abstract][Full Text] [Related]
5. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
[TBL] [Abstract][Full Text] [Related]
6. Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
Harrison SA; Bashir M; Moussa SE; McCarty K; Pablo Frias J; Taub R; Alkhouri N
Hepatol Commun; 2021 Apr; 5(4):573-588. PubMed ID: 33860116
[TBL] [Abstract][Full Text] [Related]
7. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: rationale for the development of resmetirom (MGL-3196).
Alkhouri N
Expert Opin Investig Drugs; 2020 Feb; 29(2):99-101. PubMed ID: 31868036
[No Abstract] [Full Text] [Related]
8. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.
Taub R; Chiang E; Chabot-Blanchet M; Kelly MJ; Reeves RA; Guertin MC; Tardif JC
Atherosclerosis; 2013 Oct; 230(2):373-80. PubMed ID: 24075770
[TBL] [Abstract][Full Text] [Related]
9. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Harrison SA; Bedossa P; Guy CD; Schattenberg JM; Loomba R; Taub R; Labriola D; Moussa SE; Neff GW; Rinella ME; Anstee QM; Abdelmalek MF; Younossi Z; Baum SJ; Francque S; Charlton MR; Newsome PN; Lanthier N; Schiefke I; Mangia A; Pericàs JM; Patil R; Sanyal AJ; Noureddin M; Bansal MB; Alkhouri N; Castera L; Rudraraju M; Ratziu V;
N Engl J Med; 2024 Feb; 390(6):497-509. PubMed ID: 38324483
[TBL] [Abstract][Full Text] [Related]
10. Development and validation for bioanalysis of VK2809, its active metabolite VK2809A and glutathione-conjugated metabolite MB06588 in rat liver using LC-MS/MS.
Xu ST; Jin HW; Jin X; Xu BX; Zhang Y; Xie T; Wang G; Wang J; Zhen L
J Pharm Biomed Anal; 2023 Sep; 234():115595. PubMed ID: 37487290
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.
Hu L; Gu Y; Liang J; Ning M; Yang J; Zhang Y; Qu H; Yang Y; Leng Y; Zhou B
J Med Chem; 2023 Mar; 66(5):3284-3300. PubMed ID: 36799411
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.
Kelly MJ; Pietranico-Cole S; Larigan JD; Haynes NE; Reynolds CH; Scott N; Vermeulen J; Dvorozniak M; Conde-Knape K; Huang KS; So SS; Thakkar K; Qian Y; Banner B; Mennona F; Danzi S; Klein I; Taub R; Tilley J
J Med Chem; 2014 May; 57(10):3912-23. PubMed ID: 24712661
[TBL] [Abstract][Full Text] [Related]
14. Resmetirom: First Approval.
Keam SJ
Drugs; 2024 Jun; 84(6):729-735. PubMed ID: 38771485
[TBL] [Abstract][Full Text] [Related]
15. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats.
Perra A; Simbula G; Simbula M; Pibiri M; Kowalik MA; Sulas P; Cocco MT; Ledda-Columbano GM; Columbano A
FASEB J; 2008 Aug; 22(8):2981-9. PubMed ID: 18434432
[TBL] [Abstract][Full Text] [Related]
16. Thyroid Hormone Receptor β Agonist Induces β-Catenin-Dependent Hepatocyte Proliferation in Mice: Implications in Hepatic Regeneration.
Alvarado TF; Puliga E; Preziosi M; Poddar M; Singh S; Columbano A; Nejak-Bowen K; Monga SP
Gene Expr; 2016; 17(1):19-34. PubMed ID: 27226410
[TBL] [Abstract][Full Text] [Related]
17. A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J; Waskowicz LR; Lim A; Liao XH; Lian B; Masamune H; Refetoff S; Tran B; Koeberl DD; Yen PM
Thyroid; 2019 Aug; 29(8):1158-1167. PubMed ID: 31337282
[No Abstract] [Full Text] [Related]
18. INT-767 improves histopathological features in a diet-induced
Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
[TBL] [Abstract][Full Text] [Related]
19. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression.
Bruinstroop E; Zhou J; Tripathi M; Yau WW; Boelen A; Singh BK; Yen PM
Mol Metab; 2021 Nov; 53():101266. PubMed ID: 34098145
[TBL] [Abstract][Full Text] [Related]
20. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice.
Johansson L; Rudling M; Scanlan TS; Lundåsen T; Webb P; Baxter J; Angelin B; Parini P
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10297-302. PubMed ID: 16006512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
